

PROLIGHT RECEIVES NEW MICROFLEX PATENT APPROVAL IN THE US

Prolight announces today that the US Patent and Trademark Office (USPTO), pursuant to the notice of allowance issued on March 26, has granted Prolight a patent for the analytical unit and reaction chamber for the company's point-of-care analysis system, MicroFlex, which is being developed by Prolight's partner TTP (The Technology Partnership plc).

This patent complements the patent portfolio for MicroFlex, which now consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.

The patent, US Patent No. 12,285,760, is valid until May 2040 and provides protection for the unique technical composition of the MicroFlex analytical unit and reaction chamber.

"With this granted patent Prolight strengthens the technological protection and reinforces the long-term value of the Microflex platform," said Ulf Bladin, CEO of Prolight.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight receives new MicroFlex patent approval in the US